Director, Business Development – Clinical Trial Technology; Oncology

Every cancer patient deserves access to treatment options. Massive Bio is an AI-powered precision medicine platform transforming how cancer patients discover and access clinical trials by eliminating the barriers of geography, financial constraints, and information asymmetry that have historically limited enrollment.

Every cancer patient deserves access to treatment options. Massive Bio is an AI-powered precision medicine platform transforming how cancer patients discover and access clinical trials by eliminating the barriers of geography, financial constraints, and information asymmetry that have historically limited enrollment.

Founded in 2015 and headquartered in US, Massive Bio is scaling its impact globally by powering operations across multiple countries and bringing innovative cancer treatment options to a rapidly growing and diverse population of patients. Through our proprietary AI platform, we connect individuals to clinical trials worldwide and partner with leading pharmaceutical companies, contract research organizations (CROs), and healthcare systems to accelerate drug development and expand equitable access to cutting-edge therapies.

You sell Sentinel Agent™ to oncology sponsors, then make sure every site closure it supports is documented to the standard an FDA or EMA inspector expects. Both halves are yours.

Location: United States, remote (HQ Boca Raton, FL)

• Reports to:
  
  CEO
• Level: Director
• Travel: 25-35%

You report to the CEO, with a dotted line to the Chief Medical AI Officer. About 80% of your week is business development and client delivery. The other 20% is product support: bringing what sponsors and sites tell you to the product team, and checking that what we ship matches how a study coordinator actually works a close‑out.

This seat exists because sponsor pilots are under way and the next wave needs to be sold, papered and delivered by someone who has worked on the data side. You have entered case report form (CRF) data in a US electronic data capture (EDC) system as a coordinator, or source-verified it as a monitor, and ideally both. You have conducted close‑out visits as a CRA or hosted them as the site coordinator.

Then you moved into sponsor‑facing business development. If none of that describes you, this is not the seat.

It is a player‑coach seat with no team to start. You write the proposals, run the sponsor cadence and sit in the close‑out reviews yourself. Twelve months out, the picture is a pipeline of signed pilots converting into multi‑study agreements, zero inspection findings on any close‑out we supported, and the budget to hire a clinical delivery lead. You hire them.

• Run the pipeline with the CEO. Target oncology sponsors with studies in post‑treatment or long‑term follow‑up, run the "select a study" session with clinical development, clinical operations and procurement, and turn it into a costed pilot proposal within ten business days.
• Convert pilots. Own the sponsor relationship from kickoff through readout: the weekly cadence, the gating inputs (consent language, Schedule of Assessments, EDC access, site‑entered comparison data) and the readout package. Turn the result into the next phase and a multi‑study agreement.
• Paper every engagement correctly. Statements of work under existing master agreements, including each sponsor's AI‑tool, data‑use and safety‑reporting clauses; pilot agreements and vendor qualification for new partners. Scope, sites, cohort, deliverables, acceptance criteria and billing rules are agreed in writing before work begins.
• Price off the approved rate card. You have…